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Novel and Emerging Therapies for
Inflammatory Bowel Disease
Badr Al-Bawardy1*, Raina Shivashankar2 and Deborah D. Proctor1
1Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, United States, 2Division of Gastroenterology and
Hepatology, Thomas Jefferson University, Philadelphia, PA, United States
Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn’s disease are
chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic
manifestations. Despite the availability of current biologics, such as anti-tumor necrosis
factor (anti-TNF), anti-integrins, anti-interleukins and small molecules such as tofacitinib,
the rates of primary and secondary treatment failure remain high in IBD. This highlights the
importance of continued development of new therapeutic targets and modifications of
existing ones to improve the treatment response rates and to also improve the safety
profile and tolerability of these medications. In this review we will discuss novel treatment
target agents including selective janus kinase (JAK) inhibitors, anti-interleukin (IL) (IL-12/IL-
23), leukocyte trafficking/migrating inhibitors (such as sphingosine-1-phosphate receptor
modulator) and other small molecules currently in development.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic, progressive disease that can lead to complications
including bowel damage, need for hospitalizations and surgery, decreased quality of life, and
disability. The incidence rates of IBD have been increasing world-wide. While the highest rates
have been noted in North America and Europe, increasing incidence rates have been observed in
previously low-incidence regions such as Asia as these countries become more developed (Loftus Jr,
2004; Molodecky et al., 2012; Shivashankar and Lewis, 2017a). The cause for this phenomenon is
largely unknown, however it may be related to the complex interplay between genetics and the
environment (Shivashankar and Lewis, 2017a). The latter has been implicated in the development of
IBD because of the observation that higher incidence rates are seen in industrialized nations;
therefore diet, pollution, microbial exposure, and sanitation may be involved (Molodecky and
Kaplan, 2010; Shivashankar and Lewis, 2017a).
Since IBD can be a chronic and progressive disease, optimal treatment early in the disease course
to prevent complications is paramount. The current treatment paradigm for moderate-severe
Crohn’s disease (CD) and ulcerative colitis (UC) is to use biologic therapy early to achieve
clinical remission and mucosal healing, which will ultimately decrease the risk of corticosteroid
use, surgeries, hospitalizations and increase quality of life (Klenske et al., 2019).
The currently available biologic agents include anti-tumor necrosis factor-alpha (TNF-α) agents
(infliximab, adalimumab, certolizumab, and golimumab); anti-integrin agents (vedolizumab,
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natalizumab); and an anti-interleukin (IL) 12-23 agent
(ustekinumab). Finally, tofacitinib, a non-biologic small
molecule is approved for the treatment of moderate-severe
UC. The choice between these agents depends on IBD
phenotype and behavior, previous biologic exposure and
response, potential adverse effects of therapy, patient co-
morbidities, and shared-decision making with patients.
Despite the number of available medications, there are
appreciable rates of primary non-response, loss of response, or
adverse reactions thereby necessitating additional treatment
options. Therefore, the purpose of this review article is to
describe novel and emerging therapies for IBD. In this review
we will discuss novel treatment target agents including selective
janus kinase (JAK) inhibitors, anti-interleukin (IL) (IL-12/IL-23),
leukocyte trafficking/migrating inhibitors (such as sphingosine-
1-phosphate receptor modulator) and other small molecules
currently in development (Table 1). This review will focus on
the pipeline of these new therapeutic agents and will not include
other novel and emerging therapeutic modalities such as stem cell
therapy or microbiome targeted therapies.
JAK Inhibitors
Cytokine mediators of inflammation in IBD such as IL-9, IL-12,
IL-23 and interferon-gamma (IFN-γ) are reliant on the Janus
Kinase Signal Transducer and Activator of Transcription (JAK-
STAT) pathway signaling (Salas et al., 2020). In addition, genome
wide association studies have demonstrated risk loci in the JAK
region in IBD (Barrett et al., 2008; Anderson et al., 2011).
Therefore, targeting the JAK-STAT is an appealing therapeutic
modality in IBD. JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2)
are all part of the JAK family of tyrosine kinase proteins.
Tofacitinib
Tofacitinib, a non-selective JAK inhibitor, was approved by the
US food and drug administration (FDA) in May 2018 for the
treatment of UC. The pivotal induction and maintenance clinical
trials, OCTAVE 1-3, have demonstrated efficacy of tofacitinib in
inducing and maintaining clinical and endoscopic remission in
UC (Sandborn et al., 2017b). Notably, tofacitinib was also shown
to be effective in the more refractory anti-TNF-α exposed UC
patients compared to placebo. On the other hand, a phase IIb
randomized clinical trial of tofacitinib in CD failed to meet the
primary endpoints (Panés et al., 2017). Multiple factors might
have contributed to the negative results of the study including:
study design and high placebo response rate. Subsequently, a
systematic review and meta-analysis of clinical trials of different
JAK inhibitors (tofacitnib, filgotinib, pefecitinib, upadacitinib,
TD-1473) in CD demonstrated the effectiveness of JAK inhibitors
in inducing clinical remission (Ma et al., 2019).
Tofacitinib provided the advantage being an oral agent
compared to current intravenous (IV) or subcutaneous (SC)
biologic agent formulations. The rapid onset of action of
tofacitinib is a positive feature as improvement in symptoms
of rectal bleeding and stool frequency can occur within 3 days of
starting treatment in UC patients according to post-hoc analysis
of the pivotal trials (Hanauer et al., 2019). Conversely, tofacitinib
TABLE 1 | Target, mode of delivery and development phase of emerging therapeutic agents in IBD.
Drug class Agent Target Mode of
delivery
Crohn’s disease Ulcerative colitis
JAK inhibitors Tofacitinib JAK1/JAK3 Oral N/A FDA approved
Filgotinib JAK1 Oral Phase III recruiting Phase IIb/III completed
Upadacitinib JAK1 Oral Phase III recruiting Phase III recruiting
TD-1473 Pan-JAK (gut selective) Oral Phase II recruiting Phase IIb/III recruiting
Brepocitinib (PF-
06700841)
TYK2/JAK1 Oral Phase IIa recruiting Phase IIb recruiting
PF-06651600 JAK3 Oral
BMS-986165 TYK2 Oral Phase II recruiting Phase II recruiting
Anti-trafficking
therapies
Vedolizumab SC α4β7 integrin SC N/A Phase III completed
Etrolizumab α4β7 and αEβ7 integrins SC Phase III recruiting Phase III completed
AJM300 α4 integrin Oral N/A Phase III recruiting
PF-00547659 MAdCAM SC Phase II completed Phase II completed
IL-23 inhibitors Risankizumab IL23/p19 subunit IV, SC Phase III active, not
recruiting
Phase III enrolling by invitation
Brazikumab IL23/p19 subunit IV, SC Phase IIb/III recruiting Phase 2/OLE enrolling by invitation
Mirikizumab IL23/p19 subunit IV, SC Phase III recruiting Phase III recruiting
Guselkumab IL23/p19 subunit IV, SC Phase II/III recruiting Phase II/III recruiting
S1P receptor
modulators
Ozanimod S1PR1 and S1PR5 Oral Phase III recruiting Phase III completed
Etrasimod S1PR1, S1PR4 and
S1PR5
Oral Phase II/III recruiting Phase III recruiting
Amiselimod (MT-1303) S1PR1 Oral Phase II completed N/A
PDE4 inhibitors Apremilast PDE4 Oral N/A Phase II completed
TLR9 agonist Cobitolimod TLR9 Topical
(enema)
N/A Phase IIb completed, Phase III
planned
JAK, janus kinase; TYK 2, tyrosine kinase 2; S1P, sphingosine 1 phosphate; S1PR sphingosine 1 phosphate receptor; PDE4, phosphodiesterase 4; TLR9, toll-like receptor 9; α4β7,
alpha4-beta7; αEβ7, alphaE-beta7; α4, alpha4; MAdCAM, mucosal addressin cell adhesion molecule-1; IL-23, interleukin 23; IV, intravenous; SC, subcutaneous; OLE, open label
extension.
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has been associated with increased risk of herpes zoster infection
and hyperlipidemia (Winthrop et al., 2018). In addition,
tofacitinib has a black box warning for venous
thromboembolism and mortality after risk was noted in a
subset of patients with rheumatoid arthritis taking the 10 mg
p.o. BID dose (FDA Drug Safety Communication, 2019).
Therefore, there has been an increased interest in the
development of more selective JAK inhibitors to enhance the
effectiveness and the safety profile in IBD.
Filgotinib
Filgotinib is a once daily oral small molecule with higher
selectivity for JAK 1 inhibition. JAK 1 (in addition to JAK 3)
have been shown to be expressed on both B cells and T cells
within the healthy colon mucosa (Salas et al., 2020). The efficacy
of filgotinib in CD was evaluated in a phase II, double-blinded,
placebo controlled randomized clinical trial, FITZROY. In this
trial, patients were randomized to filgotinib 200 mg once a day or
placebo and after 10 weeks based on response, patients received
either once daily filgotinib 200 mg, filgotinib 100 mg or placebo
for another 10 weeks (Vermeire et al., 2017b). A significantly
higher proportion of patients in the filgotinib groups achieved the
primary endpoint of clinical remission [defined as Crohn’s
disease activity index (CDAI) < 150] at week 10 compared to
placebo (47 vs. 23%; p  0.0077) (Vermeire et al., 2017b). In anti-
TNF-α naïve patients, the rate of clinical remission at week 10 was
60% (n  34) compared to 37% (n  26) in anti-TNF-α
experienced patients. The rate of endoscopic response and
mucosal healing in the overall filgotinib group was
numerically higher but did not reach statistical significance.
However, endoscopic assessment in this trial was limited by
short follow up time. In terms of safety, up to 20 weeks follow
up, serious infections were noted in 3% in the filgotinib group
with none reported in the placebo group.
A phase IIB/III study (SELECTION) evaluating filgotinib for
induction and maintenance therapy for moderate to severe UC
was recently completed (Feagan et al., 2020b). The induction
study included a cohort of biologic exposed and another cohort of
biologic naïve patients (Feagan et al., 2020b; Peyrin-Biroulet et al.,
2020). In each cohort patients were randomized to either
filgotinib 100 mg, filgotinib 200 mg or placebo daily. The
composite primary endpoint of endoscopic, rectal bleeding
and stool frequency (EBS) remission (defined as Mayo
endoscopic subscore ≤1, rectal bleeding subscore of 0, stool
frequency subscore decrease of 1 or more points from baseline
and ≤1) rates were significantly higher in the 200 mg filgotinib
groups (26.1% in the biologic naïve cohort and 11.5% in the
biologic experienced cohort) compared to the placebo groups.
One case of pulmonary embolism in the filgotinib 200 mg group
was noted and four total cases of herpes zoster in filgotinib groups
were noted (1 in the 100 mg group and three in the 200 mg group)
(Feagan et al., 2020b).
Patients who achieved clinical remission or response after
10 weeks of induction therapy with either filgotinib or placebo
were included in the maintenance study (Peyrin-Biroulet et al.,
2020). In this study 664 patients with moderate to severe UC who
received placebo induction remained in the placebo maintenance
arm, while patients randomized to the filgotinib induction were
re-randomized to filgotinib induction dose maintenance arm or
placebo arm (Peyrin-Biroulet et al., 2020). The composite
primary endpoint of EBS remission at week 58 was achieved
in 37.2% in the filgotinib 200 mg group vs. 11.2% in the placebo
arm (p < 0.025) and 23.8% in the filgotinib 100 mg group vs.
13.5% in the placebo arm (p < 0.05) (Peyrin-Biroulet et al., 2020).
Overall, filgotinib was well tolerated. Two cases of venous
thromboembolism were reported in the placebo arm but none
in the filgotinib group. Herpes zoster was reported in two patients
in the filgotinib arms (one in each of the filgotinib groups) but
none in the placebo groups (Peyrin-Biroulet et al., 2020).
A phase III clinical trial of filgotinib in CD is currently in
progress (NCT02914561; NCT02914600). In addition, a phase II
study evaluating filgotinib in perianal fistulizing CD is ongoing
(NCT03077412).
Upadacitinib
Upadacitinib is an oral JAK inhibitor that has high selectivity for
JAK 1 inhibition. It is currently approved for the treatment of
rheumatoid arthritis with moderate to severe activity who have
either failed or are intolerant to methotrexate. In a phase II
clinical trial (CELEST), patients with moderate to severe CD (n 
220) who failed immunosuppressants or biologics were assigned
to either placebo or upadacitinib at the following doses: 3 mg
twice a day (BID), 6 mg BID, 12 mg BID, 24 mg BID for 16-weeks
induction (Sandborn et al., 2020c). Post-induction, patients were
re-randomized to upadacitinib at the following doses: 3 mg BID,
12 mg BID, 24 mg once daily (QD) for 36 weeks (maintenance).
Although clinical remission at week 16 was not significantly
different between the treatment groups and placebo,
endoscopic remission at week 12/16 was significantly higher in
the upadacitinib groups compared to placebo (Sandborn et al.,
2020c). Higher doses of upadacitinib were associated with higher
rates of endoscopic remission in this trial.
In the phase II UC-ACHIEVE trial, moderate to severe UC
patients (n  250) who failed or were intolerant to
immunosuppressive or biologic therapy were assigned to
placebo or upadacitinib at the following once daily doses: 7.5,
15, 30, 45 mg (Sandborn et al., 2020e). Clinical remission was
significantly higher in the 15 mg (14.3%; p  0.013), 30 mg
(13.5%; p  0.011), and the 45 mg groups (19.6%; p  0.002)
compared to 0% in the placebo group. Similarly, endoscopic
improvement at week 8 (Mayo endoscopic subscore ≤1) was
significantly higher in a dose dependent manner in the
upadacitinib groups compared to placebo (Sandborn et al.,
2020e).
In terms of safety, there were a total of three cases of herpes
zoster in the upadacitinib group compared to none in the placebo
group in the CELEST trial and 1 case in the upadacitinib group
compared to none in the placebo group in the UC-ACHIEVE trial
(Sandborn et al., 2020c; Sandborn et al., 2020e). Once case of
thromboembolism occurred in a patient on the 45 mg
upadacitinib dose in the UC-ACHIEVE trial.
Currently, upadacitinib is in phase III clinical trials for CD
(NCT03345836, NCT03345823) and UC (NCT03653026,
NCT03006068, NCT02819635).
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TD-1473
TD-1473 is an oral pan-JAK inhibitor that is designed to be gut
specific to limit systemic toxicity of pan-JAK inhibition. In a
phase 1b trial, patients with moderate to severe UC (n  40) were
assigned to placebo or one of the following once daily TD-1473
doses: 20 mg, 80 mg or 270 mg) for 28 days (Sandborn et al.,
2020f). Only five of the 40 patients were exposed to anti-TNF
therapies in the past. Clinical response rate was 20% in the 20 and
80 mg groups compared to 55% in the 270 mg group while the
clinical response rate was 11% in the placebo group (no statistical
analyses performed as study not powered for outcomes)
(Sandborn et al., 2020f). There were also trends in endoscopic
improvement along with reduction in fecal calprotectin and
c-reactive protein (CRP) levels with TD-1473. Overall adverse
event rates were similar in the placebo group at 44.4 and 38.7% in
the TD-1473 groups. Phase IIb/III studies of TD-1473 for
moderate to severe UC are currently recruiting
(NCT03758443, NCT03920254). In addition, a phase II study
of TD-1473 in moderate to severe CD in underway
(NCT03635112).
TYK2 Inhibitors
TYK2 is one of the JAK-STAT family proteins. It is involved in
intracellular cytokine signaling. Brepocitinib (PF-06700841) is an
oral TYK2/JAK1 inhibitor that has been shown to be well
tolerated and effective in phase I and phase IIa studies of
patients with plaque psoriasis (Banfield et al., 2018; Forman
et al., 2020). PF-06651600 is an oral selective JAK3 inhibitor.
Phase IIa/IIb trials of combination brepocitinib (PF-06700841)
and PF-06651600 are currently recruiting for moderate to severe
CD (NCT03395184) and UC (NCT02958865).
BMS-986165 is an oral selective TYK2 inhibitor. Phase II trials
of BMS-986165 in CD (NCT03599622) and UC (NCT03934216)
are currently recruiting.
IL-12/IL-23 Inhibitors
IL-23 is a regulator of T-helper (Th)-17 cell and type 3 innate
lymphoid cell (ILC3) pathways that lead to inflammatory
cytokine production and inflammation and polymorphisms of
the IL-23 receptor gene may be associated with increased
susceptibility to CD (Feagan et al., 2017). IL-23 prevents
regulatory T-cell response in the intestine, and therefore
increases inflammation in this gut (Feagan et al., 2017; Sands
et al., 2017). Ustekinumab, which inhibits both IL-12 and the IL-
23 p40 subunit, has been shown to be effective for induction and
maintenance of remission in patients with moderate-severe CD
and UC (Feagan et al., 2016; Sands et al., 2019a).
However, it is unclear if the effect of ustekinumab ismainly driven
by its inhibition of IL-12, IL-23 or both (Deepak and Sandborn,
2017). Selective inhibition of the IL-23 pathway, which leaves the IL-
12 pathway intact, carries the potential advantage of less severe
infection and decreased malignancy risk (Deepak and Sandborn,
2017; Baker and Isaacs, 2018). A potential benefit of only blocking the
p19 subunit of IL-23 is possible increased safety since the IL-12
mediated Th1 response, which is required in the immune response to
intracellular pathogens, is left intact (Deepak and Sandborn, 2017).
Risankizumab
Risankizumab is a humanized monoclonal antibody against the
p19 subunit of IL-23. The induction dosing is provided
intravenously (IV) while the maintenance dosing is a
subcutaneous (SC) injection. A phase II trial of induction
therapy with risankizumab was conducted in patients with
moderate-severe CD; 93% of patients were previously exposed
to at least one anti-TNF agent (Deepak and Sandborn, 2017;
Feagan et al., 2017). Risankizumab (200 mg or 600 mg IV) was
compared to placebo at weeks 0, 4, and 8. The primary outcome
was clinical remission (defined as a CDAI <150) at week 12
(Feagan et al., 2017).
At week 12, those treated with risankizumab had significantly
higher rates of clinical remission vs. placebo (30.5 vs. 15.4%, p 
0.0489), clinical response (39 vs. 20.5%, 0  0.0273), endoscopic
remission (17 vs. 3%, p  0.0015), and deep remission (7 vs. 0, p 
0.0107) (Feagan et al., 2017). There was no difference in the
proportion of mucosal healing between those treated with
risankizumab (200 mg: 2%, 600 mg 7%) vs. placebo (3%)
(200 mg v. placebo, p  0.97 and 600 mg v. placebo, p  0.31)
(Feagan et al., 2017). Rates of adverse events (AEs) were similar
between those treated with placebo and risankizumab. The most
common AE was worsening of underlying CD (Feagan et al.,
2017). Other AEs included nausea, abdominal pain, arthralgia,
and headache (Feagan et al., 2017). There were no dose-related
increases in AE in those treated with risankizumab (Feagan et al.,
2017).
An open-label extension (OLE) study was completed to study
the efficacy and safety of extended IV induction and SC
maintenance therapy (Feagan et al., 2018). Those who did not
achieve deep remission in the 12-weeks induction phase of the
previously described phase II induction study received open-label
IV risankizumab 600 mg every 4 weeks for 12 weeks; patients who
were in clinical remission at week 26 were included in the
maintenance phase and received open-label SC risankizumab
180 mg every 8 weeks for 26 weeks (Feagan et al., 2018). The
following definitions were used: clinical remission (CDAI <150),
endoscopic response (>50% Crohn’s disease Endoscopic Index of
Severity [CDEIS] reduction from baseline), endoscopic remission
(CDEIS ≤4, or ≤2 for patients with isolated ileitis) (Feagan et al.,
2018). One-hundred and one patients received the extended
induction dose, and 53% (54/101 patients) were in clinical
remission at week 26 (Feagan et al., 2018). Sixty-two patients
received risankizumab maintenance therapy, and at week 52
clinical remission was maintained in 71% (44/62 patients),
81% (50/62) had clinical response, 35% (22/62) were in
endoscopic remission, 24% (15/62) had mucosal healing, and
29% (18/62) achieved deep remission (Feagan et al., 2018). There
were no new safety signals noted and the most frequent AEs
included arthralgia, headache, abdominal pain, nasopharyngitis,
nausea, and pyrexia (Feagan et al., 2018).
The long-term safety of risankizumab was studied in the phase
2 OLE study and no new safety signals were noted; 92% of
patients reported AEs and 35% of patients experienced serious
adverse events (Ferrante et al., 2020). The most common AEs
included nasopharygnitis (31%), gastroenteritis (23%), and
Frontiers in Pharmacology | www.frontiersin.org April 2021 | Volume 12 | Article 6514154
Al-Bawardy et al. Emerging Therapies in IBD
fatigue (20%) (Ferrante et al., 2020). Nine percent of patients had
serious infections while 5% of patients reported opportunistic
infections. There were no malignancies or deaths (Ferrante et al.,
2020).
Overall, risankizumab was well-tolerated and found to be
effective compared to placebo in inducing clinical remission,
response, and endoscopic remission at week 12. Currently, we
are awaiting results from phase III clinical trials (NCT03105128;
estimated study completion date February 2021). In addition, a
phase II/III clinical trial of risankizumab in ulcerative colitis is
currently recruiting (NCT03398148).
Brazikumab (MEDI 2070)
Brazikumab, a human immunoglobulin G2 monoclonal
antibody, selectively binds the p19 subunit of IL-23 (Sands
et al., 2017). Like risankizumab, the induction dose is an IV
infusion while the maintenance dose is a SC injection. A phase IIa
trial included 119 patients with moderate-severe CD who either
failed or were intolerant to anti-TNF agents; 31% of patients were
exposed to at least one anti-TNF. Patients were given either
brazikumab 700 mg IV or placebo at weeks 0 and 4, and then
received open label brazikumab 210 mg subcutaneously every
4 weeks from weeks 12 to 112 (Sands et al., 2017). The primary
outcome was clinical response (CDAI decrease of 100 points from
baseline or clinical remission [CDAI <150]) at week 8 (Sands
et al., 2017). Compared to placebo, a higher proportion of patients
treated with brazikumab achieved clinical response at week 8
(49.2% v. 26.7%, p  0.01) as well as a composite outcome of
clinical response and 50% reduction from baseline in either fecal
calprotectin or CRP concentration (42.4% v. 10%, p < 0.001)
(Sands et al., 2017). There was no difference in clinical remission
at week eight between those treated with brazikumab vs. placebo
(27.1 vs. 15%, p  0.10) (Sands et al., 2017). A similar proportion
of patients who received placebo and active treatment during the
initial double-blind period achieved clinical response, clinical
remission, the composite outcome of clinical response and at
least 50% reduction from baseline in either fecal calprotectin or
CRP concentration at week 24 (57.7 vs. 53.8%, 40.4 vs. 42.3%, and
48.1 vs. 46.2%, respectively) (Sands et al., 2017). Patients with
higher baseline serum concentration of IL-22 were found to be
more likely to responds to brazikumab than to placebo (Sands
et al., 2017; Sabino et al., 2019).
There was no difference in proportions of patients with
treatment-emergent AEs or serious AEs between placebo and
brazikumab treated groups (Sands et al., 2017). Equal numbers of
clinically significant infections occurred in patients receiving
brazikumab in both study periods and in patients receiving
placebo in the double-blind period (Sands et al., 2017). The
most common AEs included headache, nasopharyngitis, and
abdominal pain (Sands et al., 2017).
In summary, two infusions of brazikumab at weeks 0 and 4
achieved a higher rate of clinical response at week 8 compared to
placebo and continued SC dosing every 4 weeks led to ongoing
clinical response and remission at week 24 (Sands et al., 2017).
Brazikumab was generally well-tolerated in this study with
follow-up to 24 weeks (Sands et al., 2017). Of note, there was
no endoscopic evaluation or imaging as part of this phase 2a study
(Sands et al., 2017). Currently, brazikumab is in a phase IIb/III
trial in patients with CD (NCT03759288; anticipated completion
date Dec 2022) and is in a phase II/open label extension in UC
patients (NCT03616821; anticipated completion date april 2023).
Mirikizumab
Mirikizumab is an IV and SC immunoglobulin G4-variant
monoclonal antibody, and it binds to the p19 subunit of IL23
(Sandborn et al., 2020d). A phase II study of 249 patients with
moderate-severe UC was conducted to assess the efficacy and
safety of mirikizumab; 63% of patients were previously exposed to
a biologic (Sandborn et al., 2020d). Patients were randomized to
either IV placebo, mirikizumab 50 mg, or 200 mg, or
mirikizumab 600 mg at weeks 0, 4, and 8 (Sandborn et al.,
2020d). Those with clinical response to mirikizumab at week
12 were then randomized to maintenance mirikizumab 200 mg
every 4 weeks or every 12 weeks (Sandborn et al., 2020d). The
primary endpoint was clinical remission (Mayo rectal bleeding
subscore 0, with 1-point decrease from baseline for stool
frequency, and 0 or one for endoscopy) (Sandborn et al.,
2020d). Clinical remission at week 12 is as follows: 15.9%
(95% CI, 6.8–24.9; p  0.66) in the mirikizumab 50 mg group;
22.6% (12.2–33.0; p  0.004) in the mirikizumab 200 mg group;
and 11.5% (3.5–19.5, p  0.142) in the 600 mg group vs. 4.8%
(0–10) in the placebo groups (Sandborn et al., 2020d).
Endoscopic improvement at week 12 was seen in 23.8%
(13.3–34.3, p  0.12) of the mirikizumab 50 mg group; 30.6%
(23.3–34.3; p  0.0007) in the 200 mg group, and 13.1% (4.6–21.6;
p  0.215) in the 600 mg group vs. 6.3% (0.3–12.4) in the placebo
treated groups (Sandborn et al., 2020d).
Following the 12 weeks induction period, 93 mirikizumab
treated patients achieved clinical response and were randomized
to SC mirikizumab at 200 mg every 4 weeks or every 12 weeks
(Sandborn et al., 2020d). At week 52, 53.7 and 39.7% of patients
treated every 4 weeks and every 12 weeks, achieved clinical
remission, respectively (Sandborn et al., 2020d). These rates
were similar in those who were both biologic-exposed and
biologic-naïve (Sandborn et al., 2020d). Endoscopic remission
(Mayo endoscopic subscore  0) at week 52 were 14.8% (every 4
weeks) and 28.3% (every 12 weeks) (Sandborn et al., 2020d).
Durable clinical remission (clinical remission at both weeks 12
and 52) was 61.1% in the every 4 weeks maintenance dose and
38.5% in the every 12 weeks group (Sandborn et al., 2020d).
The most frequent AEs included nasopharyngitis, worsening
of UC, headache, anemia, cough, nausea; no dose related
increases in AEs were reported (Sandborn et al., 2020d).
An open label extension of this phase II study looked at the
outcome of patients treated with mirikizumab who did not
respond clinically in the initial induction period (Sandborn
et al., 2020a). These patients were randomized to either
600 mg IV mirikizumab or 1,000 mg IV mirikizumab every
4 weeks (Sandborn et al., 2020a). At week 24, those who had a
clinical response continued the maintenance period of 200 mg SC
mirikizumab (Sandborn et al., 2020a). Endpoints included
clinical remission (Mayo rectal bleeding  0, 0 or 1 with a 1
point decrease from baseline), clinical response, endoscopic
remission (Mayo endoscopic subscore  0), or endoscopic
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improvement (endoscopic subscore of 0 or 1) at weeks 24 or 52
(Sandborn et al., 2020a). In the 12 weeks extension of the
mirikizumab 600 mg dose and 1,000 mg mirikizumab dose, 50
and 43.8%, respectively, achieved clinical response and 15 and
9.4%, respectively, achieved clinical remission (Sandborn et al.,
2020a). Endoscopic improvement was seen in 20% of patients in
the 600 mg group and 15.6% of patients in the 1,000 mg group
(Sandborn et al., 2020a). In those who had clinical response at
week 24 and continued to maintenance therapy, 65.8% remained
in clinical response, 26.3% had clinical remission, and 34.2% had
endoscopic improvement at week 52 (Sandborn et al., 2020a). No
new AEs identified.
In summary, the phase II dose ranging study of mirikizumab
showed a trend toward inducing clinical remission and response
around week 12 in patients with moderate-severe UC (Sandborn
et al., 2020d). In those who did not initially respond to induction
dosing, extended IV dosing of mirikizumab for 12 additional
weeks showed a clinical response in about 50% of patients
(Sandborn et al., 2020a).
Given its efficacy in patients with UC, mirikizumab was
studied for its safety and efficacy in patients with CD in a
phase II study (Sands et al., 2019b). Patients were randomized
to mirkizumab 200 mg, 600 mg, 1,000 mg and placebo and this
was administered at weeks 0, 4, and 8 (Sands et al., 2019b). The
primary endpoint was endoscopic response (50% reduction from
baseline in SES-CD) at week 12 (Sands et al., 2019b). Endoscopic
response rates were higher in the mirkizumab groups compared
to placebo at week 12 [200 mg: 25.8% (95% CI: 10.4–41.2), p 
0.079; 600 mg: 37.5% (20.7–54.3), p  0.003; 1,000 mg: 43.8
(31.6–55.9), p < 0.001; placebo: 10.9 (3.3–18.6)] (Sands et al.,
2019b). Additionally, patient reported outcome remission rates
and CDAI response rates were greater in the 600 and 1000 mg
mirikizumab group compared to placebo (Sands et al., 2019b).
The frequencies of serious AEs and treatment-emergent AEs were
similar between placebo and treatment groups (Sands et al.,
2019b).
Mirikizumabwas also evaluated for long-term efficacy and safety
over 52 weeks in the phase II maintenance SERENITY study (Sands
et al., 2020). Patients who achieved ≥1 point improvement in SES-
CD at week 12 on mirikizumab were then re-randomized to
maintenance mirikizumab IV or SC every 4 weeks (Sands et al.,
2020). The primary endpoints were CDAI remission (<150 points),
patient reported outcome (PRO) remission (stool frequency ≤2.5
and abdominal pain ≤1 and not worse than baseline), endoscopic
response (50% reduction from baseline in SES-CD), and endoscopic
remission (SES-CD score <4 for ileal-colonic disease or <2 for
isolated ileal disease, and no subscore >1) (Sands et al., 2020).
Endoscopic response rates were 58.5 and 58.7%; PRO remission
rates were 46.3 and 45.7% in the IV and SC groups, respectively
(Sands et al., 2020). In those who achieved endoscopic response at
week 12, 69.6 and 66.7% had an endoscopic response at week 52 in
the IV and SC groups, respectively (Sands et al., 2020). Also, in those
who had endoscopic remission at week 12, 50 and 64.3%
maintained endoscopic remission at week 52, respectively, in the
IV and SC groups (Sands et al., 2020). Therewere similar treatment-
emergent AEs and serious AEs in both the IV and SC groups (Sands
et al., 2020).
Treatment with mirikizumab did have a dose-dependent
improvement in endoscopic response and remission as well as
patient-reported response and remission at week 12 in patients
with CD (Authors, 2019) (A SPECIAL MEETING REVIEW
EDITION: Highlights in Inflammatory Bowel Disease From
the 14th Congress of ECCO: A Review of Selected
Presentations From the 14th Congress of the European
Crohn’s and Colitis Organization (ECCO) * March 6–9,
2019 * Copenhagen, DenmarkSpecial Reporting on:*
VARSITY: A Double-Blind, Double-Dummy, Randomized
Controlled Trial of Vedolizumab vs. Adalimumab in Patients
With Active Ulcerative Colitis* Analyses of Data From the
VISIBLE 1 and 2 Trials: Vedolizumab in Patients With
Ulcerative Colitis or Crohn’s Disease* Improved Endoscopic
Outcomes and Mucosal Healing of Upadacitinib as an
Induction Therapy in Adults With Moderately to Severely
Active Ulcerative Colitis: Data From the U-ACHIEVE Study*
Long-Term Safety of Vedolizumab in Ulcerative Colitis and
Crohn’s Disease: Final Results From the GEMINI LTS Study*
Pediatric Crohn’s Disease Adalimumab Level-Based
Optimization Treatment (PAILOT) Randomized Controlled
Trial* Maintenance Treatment With Mirikizumab, a P19-
Directed IL-23 Antibody: 52-Week Results in Patients With
Moderately to Severely Active Ulcerative Colitis* Real-World
Effectiveness and Safety of Vedolizumab and Anti-TNF
Therapy in Biologic-Naive Patients With Ulcerative Colitis or
Crohn’s disease: Results From the EVOLVE Study* A
Randomized, Multicenter, Double-Blind, Placebo-Controlled
Study of a Targeted-Release Oral Cyclosporine Formulation in
the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy
Results* Real-World Analyses of PatientsWith IBD TreatedWith
VedolizumabPLUS Meeting Abstract Summaries With Expert
Commentary by: Edward V. Loftus Jr, MD Professor of Medicine
Division of Gastroenterology and Hepatology Mayo Clinic
Rochester, Minnesota, 2019). Mirikizumab also had been
shown to have sustained efficacy to week 52 (Sands et al.,
2020). Mirkizumab for CD is currently being studied in a
phase III trial (NCT03926130). Phase III Induction,
maintenance and open label extension studies are currently
recruiting for UC (NCT03518086, NCT03524092,
NCT03519945).
Guselkumab
Guselkumab is an IV and SC anti-IL23 that is currently approved
for the treatment of moderate-severe plaque psoriasis (Sandborn
et al., 2020i). GALAXI 1 is a phase II study that evaluated the
efficacy and safety of guselkumab in patients with moderate-
severe CD who either had intolerance or inadequate response to
corticosteroids, immunosuppressive agents and/or biologics
(Sandborn et al., 2020i). Patients were randomized to
guselkumab 200 mg, 600 mg, or 1,200 mg at weeks 0, 4, and 8;
ustekinumab (the reference arm) ∼6 mg/kg IV at week 0 and
90 mg SC at week 8; or placebo IV (Sandborn et al., 2020i).
Outcomes of interest included change in CDAI scores compared
to baseline, clinical remission (CDAI < 150) and response, clinical
biomarker response (clinical response and ≥50% reduction from
baseline in CRP or fecal calprotectin), endoscopic response, and
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safety (Sandborn et al., 2020i). Two-hundred and fifty CD
patients were included in this study and about 50% had failed
biologics (Sandborn et al., 2020i). There were significant
decreases of CDAI from baseline in all guselkumab groups
compared to placebo at week 12 (Sandborn et al., 2020i).
Compared to placebo, there was a higher proportion patients
in all guselkumab groups who achieved clinical remission
(200 mg: 54%, 600 mg: 56%, 1,200 mg: 50%, placebo: 15.7%),
clinical biomarker response (200 mg: 54%, 600 mg: 48%,
1,200 mg: 42%, placebo: 11.8%), and endoscopic response
(200 mg: 36%, 600 mg: 40%, 1,200 mg: 36%, placebo: 11.8%)
(Sandborn et al., 2020i). In those who failed biologics, 45.5%
(35/77) in the guselkumab group and 12.5% (3/24) in the placebo
group achieved clinical remission at week 12 (Sandborn et al.,
2020i). The rates of AE, infections, and serious AE were similar
across all guselkumab treatment arms compared to placebo
(Sandborn et al., 2020i).
In summary, in patients with moderate-severe CD,
guselkumab was more efficacious in terms of clinical response,
remission, endoscopic response, and clinical-biomarker response
compared to placebo. There was no clear dose-response in this
phase II study (Sandborn et al., 2020i). Guselkumab Is currently
in phase II/III trials with an estimated study completion date in
October 2024 (NCT03466411).
Additionally, a phase IIb/III study of the safety and efficacy of
guselkumab in patients with moderate-severe UC was started in
September 2019 (NCT04033445; anticipated completion by July
2025). In addition, a phase IIa study is evaluating combination
treatment of guselkumab and golimumab in moderate-severe UC
(NCT03662542) (Hanzel and D’Haens, 2020).
IL-6 Inhibitors
PF-04236921
PF-04236921 is a fully human immunoglobulin G2 monoclonal
antibody that binds IL-6, which has many pro-inflammatory
effects. A phase II study (ANDANTE I) aimed to evaluate the
efficacy and safety of PF-04236921 in patients with moderate-to-
severe CD who had inadequately responded to anti-TNF therapy
(Danese et al., 2019). This study was then followed by an open-
label extension study (ANDANTE II) with the primary aim of
studying long-term safety, tolerability, and immunogenicity. For
the phase II study, patients were randomized 1:1:1:1 to receive
placebo or PF-04236921 10, 50, or 200 mg SC on days 1 and 28.
The primary endpoint for the induction study was CDAI-70
response at weeks 8 or 12. Secondary endpoints included CDAI-
70 and CDAI-100 response rates, CDAI remission (CDAI score
<150). The primary aim of the OLE study was safety (Danese
et al., 2019).
In the induction study PF-04236921 50 mg was found to have
significantly higher CDAI-70 rates compared to placebo at weeks
8 (49.3 vs. 30.6%, p < 0.05) and 12 (47.4 vs. 28.6%, p < 0.05)
(Danese et al., 2019). CDAI remission rates with PF-04236921
50 mg daily were significantly higher at week 12 compared to
placebo 27.4 vs. 10.9%, p < 0.05) (Danese et al., 2019). The PF-
04236921 10 mg dose did not meet the primary end point.
One-hundred and nine one patients entered the OLE study,
and 89 (46%) were CDAI responders at OLE baseline. A majority
of patients (77.8%) had their PF-04236921 dose escalated to
100 mg between weeks 8 and 48. In those who had been on
drug in the induction period (n  65), the HBI response and
remission rates were 40 and 32%, respectively, at week 48 (Danese
et al., 2019). It was rare to find antidrug antibodies. One out of
680 serum samples (0.1%) were found to be positive for anti-drug
antibody (at week 4 with dose of 50 mg). CRP levels were noted to
be suppressed during the OLE treatment period.
The most common serious adverse effects with CD-related,
such as worsening of CD and abdominal pain, and
nasopharyngitis. In the OLE study, most AEs were mild-
moderate in severity. One death occurred in the induction
study, and this was in the 50 mg group; the patient died of
respiratory failure secondary to pneumonia and was thought
to be unrelated to the treatment. Cases of GI perforation and GI
abscesses were seen in the induction and OLE studies of patients
on PF-04236921; most cases were identified in areas of previous
disease involvement or surgery.
In summary, in patients with moderate-severe CD, PF-
04236921 50 mg was more efficacious than placebo in
inducing response and remission at week 12. In those in the
OLE, who were initially on active drug during the induction
period, about 40% had an HBI response rate at week 48. There are
signals of GI perforation and abscess in the PF-04236921
treatment groups, and therefore this signal will need to be
carefully monitored in any future clinical trials. At this time
there are no phase three trials of PF-04236921.
Human IL-22Fc Fusion Protein
UTTR1147A
The activation of the IL-22 pathway may help to increase
epithelial tight junctions, promote mucus production, and lead
to secretion of antimicrobial peptides (Rothenberg et al., 2019).
Ultimately this pathway may promote tissue regeneration, and
therefore it is a valuable treatment target. UTTR1147A (IL-22Fc)
is a fusion protein consisting of a linked human IL-22 and
crystallizable fragment (Fc) of the human IgG4 (Rothenberg
et al., 2019). A recent phase 1a trial studied single, ascending
intravenous (1–120 μg/kg) and subcutaneous (3–120 μg/kg)
doses of UTTR1147A on safety and tolerability in healthy
volunteers (Rothenberg et al., 2019). The maximum tolerated
IV dose was 90 μg/kg and most common AEs were dose-
dependent but reversible skin effects. UTTR1147A increased
proportionally to the doses given, and this caused elevations of
IL-22 signaling biomarkers without causing systemic
inflammation. Thus, preliminary data shows that UTTR1147A
promotes the IL-22 signaling pathway and may lead to tissue
regeneration without immunosuppression. This would be a novel
mechanism of action in those with epithelial injury, such as what
occurs in patients with IBD.
A phase Ib study analyzed UTTR1147A in healthy volunteers
and UC patients. 38 healthy volunteers and 24 UC patients were
given UTTR1147A or placebo at doses ranging between
30–90 μg/kg either weekly or monthly (6:2 UTTR1147A:
placebo per cohort) (Wagner et al., 2020). The Mayo Clinic
score was evaluated at baseline, day 30, and day 85. The study
found that UTTR1147A was safe and well tolerated in both
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groups of patients and most common side effects were
dermatologic effects of dry skin, erythema, and pruritis.
Interestingly, at the same dose level, UC patients had relatively
lower drug exposures than healthy volunteers and this was
thought to be due to faster drug clearance (Wagner et al.,
2020). Additionally, UC patients had attenuated
pharmacodynamics response (production of biomarkers such
as CRP) compared to healthy volunteers (Wagner et al., 2020).
However, this study showed that there was an adequate safety and
PK profile in both cohorts, and UTTR1147A did produce
pharmacodynamics biomarkers in both cohorts. Further data
would be important to study this novel mechanism of action in
the treatment of patients with IBD.
Anti-Adhesion Molecules
Migration of pro-inflammatory T cells into the gut facilitates
inflammation which is characteristic of CD and UC (Targan et al.,
2007; Lin et al., 2015; Shivashankar and Pardi, 2017b). Interaction
between surface-expressed α4β1 and α4β7 integrins on
lymphocytes and adhesion molecules [vascular cell adhesion
molecule-1 (VCAM-1) or mucosal addressin cell adhesion
molecule-1 (MAdCAM-1)], which are present on endothelial
cells, allow for activated effector T cells to target the gut
(Shivashankar and Pardi, 2017b). This interaction allows for
movement of T cells out of the blood stream and into the
gastrointestinal tract (Sugiura et al., 2013; Shivashankar and
Pardi, 2017b; Sandborn et al., 2020b). Natalizumab (NAT), a
humanized IgG4 monoclonal antibody that targets the α4-
integrin subunit of α4β1 and α4β7 on the surface of
lymphocytes, has been approved for CD and multiple sclerosis
since it blocks lymphocyte trafficking to the gut and brain. NAT
has been associated with progressive multifocal
leukoencephalopathy (PML) (Feagan et al., 2013; Park and
Jeen, 2018). On the other hand, vedolizumab (VDZ) is a
humanized IgG1 monoclonal antibody that specifically targets
the α4β7 integrin, and it has been approved for UC and CD and
therefore selectively prevents leukocyte migration to the gut
(Feagan et al., 2013; Park and Jeen, 2018). In this section, we
will focus on novel anti-adhesion molecules and a novel method
of administration of VDZ.
SC Vedolizumab
VDZ, an infusion medication, was approved in 2014 for
moderate-severe UC and CD. From clinical trial data, CD
patients who responded to induction dosing at week 6 were
more likely to achieve clinical remission, clinical response, and
corticosteroid-free remission at week 52 compared to placebo
(Sandborn et al., 2013). In addition, UC patients treated with
VDZ in clinical trials had a significantly higher rate of clinical
remission, clinical response, mucosal healing, and corticosteroid-
free remission at week 52 compared to placebo (Feagan et al.,
2013).
A new SC formulation of VDZ has been studied in those with
UC; the benefit of this formulation is its convenient route of
administration for patients who would like to avoid maintenance
IV infusion therapy. A phase III open-label study (VISIBLE 1) of
patients with moderate-severely active UC was conducted to
assess the efficacy of SC VDZ as maintenance therapy
(Sandborn et al., 2020b). The primary endpoint was clinical
remission (total Mayo score ≤2 and no subscore >1) at week
52. VDZ 300 mg IV was administered at weeks 0 and 2 (Sandborn
et al., 2020b). Those with clinical response at week 6 were then
randomized to maintenance treatment with SC VDZ 108 mg
every 2 weeks, IV VDZ 300 mg every 8 weeks, or placebo
(Sandborn et al., 2020b). SC VDZ had a higher rate of clinical
remission at week 52 compared to placebo in both anti-TNF
naïve and anti-TNF exposed patients (53.7 vs. 18.9%, p < 0.01 and
33.3 vs. 5.3%, p  0.023, respectively) (Sandborn et al., 2020b).
There were also significantly higher rates of endoscopic
improvement (56.6 vs. 21.4%, p < 0.001) and durable clinical
response (64.2 and 28.6%, p < 0.001) when SC VDZ was
compared to placebo (Sandborn et al., 2020b). There was no
significant difference between SC VDZ and placebo in terms of
durable clinical remission (15.1 vs. 5.4%, p  0.076) or
corticosteroid-free remission (28.9 vs. 8.3%, p  0.067)
(Sandborn et al., 2020b). Endpoints were generally similar
between SC VDZ and IV VDZ.
There were no new safety signals when SC VDZwas compared
to IV VDZ. The most common AE was worsening of UC disease
activity, nasopharyngitis, upper respiratory infections, and
anemia (Sandborn et al., 2020b). Eleven patients (10.4%)
receiving SC VDZ had injection-site reactions characterized by
rash, swelling, erythema, and pruritis (Sandborn et al., 2020b).
There were no cases of PML or deaths. The VDZ
pharmacokinetics achieved with SC VDZ was similar to that
of the IV formulation (Sandborn et al., 2020b).
Overall, this study showed that SC vedolizumab was effective
and well-tolerated as maintenance therapy for UC following an
induction with IV VDZ. Efficacy outcomes were generally similar
between maintenance SC VDZ and IV VDZ. Also, the safety
profile was encouraging, and no new safety signals were
identified. SC VDZ will give patients an option for an
alternate mode of administration if they prefer to avoid long-
term infusions. SC VDZ for moderate-severe UC will potentially
be available in 2022.
Etrolizumab
While VDZ targets only the α4β7 integrin, etrolizumab is a SC
humanized monoclonal anti-integrin antibody that selectively
binds the β7 subunit of both α4β7 and αEβ7 integrins (Vermeire
et al., 2014; Sandborn et al., 2020h). Therefore, etrolizumab
controls movement of inflammatory cells into the
gastrointestinal tract and also mediates inflammatory effects
on the gut mucosa (Vermeire et al., 2014; Sandborn et al.,
2020h). The phase II EUCALYPTUS study showed that
etrolizumab was beneficial over placebo in patients with
moderate-severe UC (Vermeire et al., 2014). In this study, 124
patients were randomized to two doses of SC etrolizumab—either
100 mg at weeks 0, 4, and 8 with placebo at week 2; or 420 mg
loading lose (LD) at week 0, followed by 300 mg at weeks 2, 4, and
8—or placebo (Vermeire et al., 2014). The primary endpoint was
clinical remission at week 10 (Mayo clinic score ≤2 with no
individual subscore >1). Compared to placebo (0 patients in
clinical remission), etrolizumab (100 mg: 21%, p  0.004; LD+
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300 mg: 10%, p  0.048) treatment was found to lead to a higher
proportion of patients in clinical remission at week 10 (Vermeire
et al., 2014). Adverse events occurred at a similar frequency across
all groups—61% of 100 mg etrolizumab group, 49% in the LD+
300 mg group, and 72% in the placebo group. No patients
developed PML.
Etrolizumab has an extremely active phase III clinical trial
program and includes direct comparisons to infliximab and
adalimumab. There are currently six randomized controlled
trials and two open label extension studies. The aim of
HIBISCUS I and II (identical induction trials of etrolizumab
105 mg vs. adalimumab and placebo), GARDENIA (maintenance
study studying etrolizumab 105 mg vs. infliximab), and LAUREL
(maintenance trial evaluating etrolizumab 105 mg against
placebo) is to study UC patients who are anti-TNF naïve.
HICKORY is a maintenance trial studying etrolizumab 105 mg
vs. placebo in anti-TNF exposed UC patients (Sandborn et al.,
2020h). The primary endpoints are based on clinical response (≥3
point decrease and 30% reduction in Mayo clinic score and ≥1
point decrease in rectal bleeding or an absolute rectal bleeding
score of 0 or 1), remission (MCS ≤2, with individual subscore ≤1
and rectal bleeding score of 0) at each trial’s specified time points
(Sandborn et al., 2020h). COTTONWOOD is the open-label
extension and safety monitoring study of UC patients treated
with etrolizumab who were followed until week 108 (Sandborn
et al., 2020h).
Early results from the HICKORY study included 130 UC
patients and 45% had previously been exposed to ≥2 anti-TNFs
(Peyrin-Biroulet et al., 2017). Stool frequency rates improved
from baseline to week 4 in 30% and at week 14 in 50% of patients
(Peyrin-Biroulet et al., 2017). Rectal bleeding remission rates were
observed from baseline to week 4 in about 30% of patients and at
week 14 in about 50% of patients (Peyrin-Biroulet et al., 2017).
Biomarkers decreased at week 14 (fecal calprotectin: mean 57%
decrease; CRP: 33% decrease) (Peyrin-Biroulet et al., 2017).
Therefore, in patients previously exposed to anti-TNFs,
etrolizumab led to symptom improvement as early as week 4
(Peyrin-Biroulet et al., 2017).
For patients with CD, the BERGAMOT study is an induction
andmaintenance trial evaluating anti-TNF naïve and experienced
patients (etrolizumab 105 and 210 mg vs. placebo) (Sandborn
et al., 2020h). Eligible patients may enter JUNIPER study, which
will be the open label extension of etrolizumab 105 mg (Sandborn
et al., 2020h). The co-primary endpoint for BERGAMOT is
clinical remission (unweighted abdominal pain score ≤1 and
stool frequency ≤3) and endoscopic improvement (>50%
reduction in SES-CD from baseline) at weeks 14 and 62
(Sandborn et al., 2020h). The primary outcome for JUNIPER
is long term efficacy (clinical remission assessed at 12 weeks
intervals), endoscopic remission (SES-CD ≤4 [≤2 for pts with ileal
disease] with no segment >1) at week 108 and incidence and
severity of AEs (Sandborn et al., 2020h).
The BERGAMOT induction cohort included 300 CD patients
who were randomized to etrolizumab 105 mg SC every 4 weeks,
210 mg at weeks 0, 2, 4, 8, and 12, or placebo for a 14 weeks
induction period (Selinger et al., 2018). Previous anti-TNF
exposure was noted in 73% of patients (Selinger et al., 2018).
Symptomatic remission was seen in a greater number of patients
treated with etrolizumab [105 mg: 20.8% (90% confidence
interval 15.4–27.5); 210 mg: 24.8 (18.9–31.8)] compared to
placebo (11.9 [6.6–20.5]) at week 14 (Selinger et al., 2018).
Similarly, more patients treated with etrolizumab (105 mg: 21
[15.6–27.8] and 210 mg: 17.4 [12.4–23.7] achieved endoscopic
improvement compared to placebo (3.4 [1.1–9.7]) at week 14
(Selinger et al., 2018). AEs were comparable between etrolizumab
and placebo; there were no cases of PML or death (Selinger et al.,
2018).
In addition to providing further data on clinical response,
remission, and endoscopic remission data for etrolizumab, these
data may help clinicians decide which biologic is an ideal first-line
agent for their patient (Sandborn et al., 2020h). The HIBISCUS I
and II and GARDENIA studies will be the first phase III trials in
UC to study the efficacy of a novel agent directly compared to
another agent, i.e., infliximab and adalimumab (Sandborn et al.,
2020h).
AJM300
α4 or α4β7 targets have been shown to be possible therapeutic
targets in the treatment of IBD since suppression of these
integrins have controlled development of colitis in an animal
model (Sugiura et al., 2013). A variety of small molecule α4
integrin antagonists have been studied in clinical trials for
conditions such as asthma and multiple sclerosis. AJM300 is
an oral small molecule that targets α4 integrin, and it is classified
as a phenylalanine derivative (Yoshimura et al., 2015). This small
molecule’s duration of action is very short, within one day of last
dose as described in a phase IIa study (Yoshimura et al., 2015).
AJM300 has been shown to be effective in experimental colitis
model in mice; this study showed that the active metabolite of
AJM300 inhibited the binding of α4β1/α4β7 integrin-expressing
cells to VCAM-1/MAdCAM-1 in vitro (Sugiura et al., 2013).
Given the α4 blockade, there may be a potential risk for PML in
AJM-300 therapy (Yoshimura et al., 2015).
A phase IIa study including 102 patients with moderate active
UC was conducted to assess the primary outcome measure of
clinical response (decrease in Mayo score of at least 3 points and
decrease of at least 30% from baseline, with decrease in rectal
bleeding subscore of at least 1 point or an absolute rectal bleeding
score of 0 or 1) at week 8 (Yoshimura et al., 2015). Patients who
had inadequate response or intolerance to mesalamine or
corticosteroids were given AJM300 960 mg orally or placebo
three times daily for 8 weeks (Yoshimura et al., 2015).
Compared to placebo, those treated with AJM300 had higher
rates of clinical response (62.7 vs. 25.5%, p  0.0002), clinical
remission (23.5 vs. 3.9%, p  0.0099), and mucosal healing (58.8
vs. 29.4%, p  0.0014) (Yoshimura et al., 2015).
There was a significant increase in peripheral leukocyte count
as would be expected from an anti-α4 integrin; this increase was
seen as early as week 2 (Yoshimura et al., 2015). However, this
finding normalized the day after the last dose given at week 8
thereby suggesting a short duration of action (Yoshimura et al.,
2015). The most common adverse events were nasopharyngitis
and UC, with higher AEs seen with UC in the placebo group
(Yoshimura et al., 2015). Overall, however, there were similar
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rates of AEs observed between the treatment and placebo arms
(Sabino et al., 2019). There were no serious AEs observed, and
infection, and PML were not seen in this study (Yoshimura et al.,
2015).
In summary, AJM-300 was more effective than placebo in
inducing clinical response, clinical remission, and mucosal
healing in moderately active UC patients who had only been
exposed to mesalamine or steroids in the past. However, the study
was limited by a small sample size and a short study duration (8
weeks) (Yoshimura et al., 2015). Unfortunately, there were
extremely low number of patients who were intolerant or
inadequately responding to steroids in this study, and there
was no information on exposure to immunomodulators and
anti-TNFs (Yoshimura et al., 2015). AJM300 is currently in
phase III trials for UC patients, and the estimated study
completion date is February 2021 (NCT03531892).
Abrilumab (AMG 181or MEDI 7183)
Abrilumab is an injectable fully human monoclonal
immunoglobulin G2 antibody that targets the α4β7 integrin
and prevents interaction with MADCAM-1 (Sandborn et al.,
2017a). Abrilumab has a high bioavailability after SC dosing and a
long half-life (about 31 days) (Sandborn et al., 2019).
A phase IIb study in patients with CD who had inadequate or
loss of response or intolerance to immunosuppressives, anti-
TNFs, or corticosteroids were randomized to receive placebo
or abrilumab (21 mg or 70 mg) SC on day 1, weeks 2 and 4, and
then every 4 for 24 weeks, or one dose of abrilumab 210 mg SC on
day 1 (Sandborn et al., 2017a). The primary endpoint was clinical
remission (CDAI < 150) at week 8 (Sandborn et al., 2017a). There
was no significant difference in clinical remission at week 8
between abrilumab at any dose when compared to placebo
(Sandborn et al., 2017a). Of note, there were higher rates of
clinical remission at week 12 in those treated with a single dose of
abrilumab 210 mg when compared to placebo in those who
previously failed anti-TNF therapy (Sandborn et al., 2017a).
AE rates were similar among all groups through week 24, and
there were no cases of PML or death (Sandborn et al., 2017a).
A phase II induction and sustained remission study of
abrilumab was conducted in patients with active moderate-
severe UC who did not respond or lost response to usual
medical therapy (Sandborn et al., 2019). Patients were
randomized to SC placebo or abrilumab (7, 21, 70 mg) on day
1, week 2, week 4, and then every 4 weeks thereafter until week 24
or a single dose of 210 mg abrilumab on day 1 followed by placebo
at the same dosing scheduled noted previously until week 24
(Sandborn et al., 2019). An open-label phase of the study involved
administration of abrilumab 210 mg once every 3 months
(Sandborn et al., 2019). The primary endpoint was remission
(total Mayo score ≤2 points with no individual sub-score >1
point) at week 8 (Sandborn et al., 2019). There were significantly
higher odds of achieving clinical remission, clinical response, and
mucosal healing at week 8 in those treated with abrilumab 70 and
210 mg compared to placebo (Sandborn et al., 2019). In those
with prior anti-TNF failure, there were greater clinical remission
rates at week 8 in the abrilumab 70 and 210 mg dose (Sandborn
et al., 2019).
However, there were no clear benefits of abrilumab treatment
at week 24—in this study, patients continued their initial
treatment regardless of whether they responded after the
induction period (Sandborn et al., 2019). The odds of
sustained remission did increase in patients who continued to
take multiple doses of abrilumab 70 mg every 4 weeks compared
to placebo (Sandborn et al., 2019).
There were no differences in AEs across treatment groups
through week 24. The most common AE were non-serious
infections, gastrointestinal effects, headache, and arthralgia
(Sandborn et al., 2019). The only serious AE noted in more
than one patient in the abrilumab treated group was worsening of
UC (Sandborn et al., 2019). There were no cases of PML or death.
Ten patients (8.6%) in the placebo group and 9 (3.8%) in the
abrilumab group reported neoplasms (Sandborn et al., 2019). A
limitation of this phase II study of abrilumab in UC include its
short duration; phase III studies are needed to assess the long-
term response of the 70 mg dose after 24 weeks (Sandborn et al.,
2019).
In conclusion, while the phase II study of abrilumab in CD
failed to meet its primary endpoint, the study in UC patients
showed efficacy at week 8 with higher rates of clinical remission,
clinical response, and mucosal healing. Since there was no clear
benefit of abrilumab at week 24 in UC patients, longer term phase
III studies are required to better assess this finding. Phase 3
studies have not yet started.
PF-00547659 (SHP647)
PF-00547659 is a SC fully humanmonoclonal antibody that binds
to MAdCAM, thereby decreasing lymphocyte trafficking to the
gut and leading to decreased gastrointestinal inflammation
(Sandborn et al., 2018). A phase II dose ranging study of PF-
00547659 was conducted in patients with moderate-severe CD
who have a history of failure or intolerance to
immunosuppressives and/or anti-TNF therapy (Sandborn
et al., 2018). This study included 265 patients who were
randomized to PF-00547659 22.5, 75 mg, or 225 mg or placebo
(Sandborn et al., 2018). The primary endpoint was a CDAI 70-
point decrease from baseline at week eight or 12 (Sandborn et al.,
2018). There was no significant difference in CDAI response
between the treatment group and placebo at week 8 (22.5 mg:
52.7%, 75 mg: 60.1%, 225 mg: 62.7%) or 12 (22.5 mg: 62%, 75 mg:
64.7%, 225 mg: 57.5%); this was likely due to a high clinical
response in the placebo group (47.7% at week 8 and 58.6% at week
12) (Sandborn et al., 2018).
In a post-hoc analysis, the proportions of patients who
achieved clinical remission were higher in all PF-00547659
dose groups than in placebo at weeks 8 and 12 in those with
higher inflammatory burden as evidenced by higher median high
sensitivity CRP values (>5 mg/L or >18.8 mg/L) or higher
baseline SES-CD scores (>17) at baseline (Sandborn et al.,
2018). The incidence of AEs, serious AEs, and discontinuation
was similar across all treatment groups.
The long-term safety and efficacy portion of the study followed
patients for a further 6 months (D’Haens et al., 2018a). The most
common AEs with treatment included nasopharyngitis (5.6%),
arthralgia (6.0%), and headache (5.2%) (D’Haens et al., 2018a).
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There were two deaths (multiorgan failure after postoperative
aspiration following resection of the terminal ileum and
metastatic adenocarcinoma of unknown primary) however
neither were thought to be drug related (D’Haens et al.,
2018a). Harvey Bradshaw Index response rates were sustained
over 6 months of treatment (D’Haens et al., 2018a).
A post-hoc analysis also looked at endoscopic outcomes
following induction therapy with PF-00547659 (D′Haens et al.,
2018b). Mean total SES-CD scores across four colon and one ileal
segments were found to trend toward a decrease across all
treatment arms (except for the 75 mg dose) (D′Haens et al.,
2018b). The 22.5 mg dose showed the largest trend toward
improvement in endoscopic disease severity (mean change
from baseline to week 10 at 22.5 mg dose: 4.0; 75 mg: 0;
225 mg: −1; placebo: 1.5) (D′Haens et al., 2018b). However, no
consistent association between clinical and endoscopic
improvement was observed (D′Haens et al., 2018b).
In patients with moderate-severe UC, a phase II study that
evaluated the efficacy and safety of PF-00547659 in 357 patients
who had failed or were intolerant to at least one usual therapy
found the drug to be superior to placebo (Vermeire et al., 2017a;
Sabino et al., 2019). The primary endpoint was clinical remission
(Mayo score ≤2 with no individual subscore >1 and rectal
bleeding subscore ≤1) at week 12 (Vermeire et al., 2017a). The
remission rates in those treated with PF-00547659 (7.5 mg:
11.3%; 22.5 mg: 16.7%; 75 mg: 15.5%; 225 mg: 5.7%) were
higher than placebo (2.7%) at week 12; the 225 mg dosing did
not achieve statistical significance compared to placebo
(Vermeire et al., 2017a). Similar to the findings from the CD
trial, PF-00547659 was overall well-tolerated (Vermeire et al.,
2017a).
In conclusion, in patients with CD, PF00547659 was not
significantly different compared to placebo in achieving
clinical response at weeks 8 or 12 likely due to high placebo
response rates (Sabino et al., 2019). On the other hand, three out
of four doses of PF00547659 did achieve significantly higher rates
of clinical remission than placebo in patents with UC. Phase III
studies in patients with IBD have not yet been announced.
Oral Anti-tumor Necrosis Factor Agents
Anti-TNF agents were the first class of biologics approved for the
treatment of moderate to severe UC and CD. They have
revolutionized the treatment paradigm of IBD and have
proven to be effective (Sands et al., 2004; Rutgeerts et al.,
2005; Hanauer et al., 2006; Sandborn et al., 2007; Schreiber
et al., 2007). One of the limitations of current anti-TNF agents
is that they are currently administered by IV or as SC injectables
only. This is associated with risk of infusion/injection reactions,
systemic side effects and increased cost of repeated infusions/
injections. An oral and intestinally restricted anti-TNF agent
would help overcome some of these challenges of current anti-
TNF agents.
AVX-470
AVX-470 is an oral polyclonal immunoglobulin that is derived
from the colostrum of cows that have been immunized with
human recombinant anti-TNF. In the first human study, 36
patients with UC received either AVX-470 (pH dependent
delayed release capsules) at doses of 0.2, 1.6, and 3.5 g/day or
placebo (Harris et al., 2016). In terms of safety, AVX-470 was well
tolerated and the total rate of AEs was 52% compared to 78% in
the placebo group. At 4 weeks, the overall clinical response and
remission rates were 25.9 and 3.7% in the AVX-470 group
compared to 11.1 and 0% in the placebo group, respectively.
Endoscopic remission was achieved in 7.4% in the AVX-470
group compared to none in the placebo group. In term of
immunogenicity, no human anti-bovine antibodies were
detected.
OPRX-106
OPRX-106 is an oral anti-TNF agent. It is a combination of plant
cell-expressed human anti-TNF receptor II fused to IgG1 Fc
domain. The plant cells function as a delivery mechanism. A
phase II randomized, 2-arm, open label clinical trial of 25 patients
with UC treated with OPRX-106 at 2 or 8 mg daily for 8 weeks
was performed (Almon et al., 2020). A total of 18 patients
completed the study. Clinical response defined as a decrease in
the Mayo score by at least 3 points was achieved in 67% and
clinical remission (Mayo score ≤2 without sub-score being greater
than 1) was achieved in 28%. Mucosal healing (Mayo endoscopic
score ≤1) was achieved in 33% (Almon et al., 2020). In terms of
immunogenicity, no anti-drug antibodies were detected.
Oral anti-TNF agents have the potential of enhanced safety,
decreased immunogenicity and higher patient acceptance.
Although promising, the current available data on efficacy and
safety of oral anti-TNF agents is limited and future larger trials




Sphigosine-1-phosphate is a sphingolipid ligand of G protein
coupled receptors (S1P1-S1P5) which are responsible for
controlling the egress of lymphocytes from lymphoid organs.
The S1P/S1PR interaction can also result in internalization of the
S1PR which leads to decrease lymphocyte release from the
lymphoid tissue into the circulation. Fingolimod was the first
S1P receptor modulator approved for the treatment of multiple
sclerosis in 2010 (Cohen et al., 2010; Kappos et al., 2010).
Fingolimod is a non-selective S1P receptor modulator and has
high affinity for S1PR 1 and S1PR3-5. Although overall well
tolerated, fingolimod has been associated with adverse events
such as bradycardia, hypertension, infection and elevated liver
tests (Danese et al., 2018).
Ozanimod
Ozanimod is a S1P receptor modulator with selective affinity for
S1PR1 and S1PR5. It was approved by the US FDA in 2020 for the
treatment of relapsing MS (Cohen et al., 2016; Cohen et al., 2019;
Comi et al., 2019).
TOUCHSTONE is a phase II double blind, randomized
clinical trial of ozanimod 0.5 or 1 mg vs. placebo daily in
moderate to severe UC (n  197). The primary outcome was
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clinical remission at 8 weeks (Mayo clinic score ≤2; No sub-score
> 1). The primary outcome was achieved in 16% in the ozanimod
1 mg group vs. 14% in the ozanimod 0.5 mg group vs. 6% in the
placebo group (p  0.048 and p  0.14, respectively) (Sandborn
et al., 2016). Mucosal healing at week 8 (defined as Mayo
endoscopy sub-score ≤1) was achieved in 34% in the 1 mg
group vs. 28% in the 0.5 mg group compared to 12% in the
placebo group (p  0.002 and p  0.03, respectively). At week 32,
clinical remission was 21% in the 1 mg group and 26% in the
0.5 mg group compared to 6% in the placebo group (p  0.01 and
p  0.002, respectively). Mucosal and histologic healing rates were
similarly significantly higher in the ozanimod groups compared
to placebo at 32 weeks (Sandborn et al., 2016). In the ozanimod
groups, one patient developed bradycardia (patient had previous
history of bradycardia) and four patients developed elevated liver
enzymes.
TRUE-NORTH is a phase III randomized, double-blind,
placebo-controlled trial of induction and maintenance
ozanimod in UC completed in 2020 (Danese et al., 2020a;
Sandborn W. et al., 2020). In the induction phase of 10 weeks,
moderately to severely active UC patients received either
ozanimod 1 mg or placebo daily. The primary endpoint of
clinical remission (based on 3-component Mayo score) was
met in 18.4% in the ozanimod group vs. 6% in the placebo
group (p < 0.0001) (Sandborn W. et al., 2020). Clinical remission
was numerically higher then placebo but did not achieve
statistical significance in the anti-TNF exposed patients who
received ozanimod (10 vs. 4.6%; p  0.195). Secondary
outcomes of clinical response, endoscopic improvement and
mucosal healing (both endoscopy and histology) rates were
significantly in the total ozanimod group compared to placebo.
The reported rate of bradycardia was 0.5% in the
ozanimod group.
In the maintenance trial, 457 moderate to severe UC patients
who achieved clinical response after 10 weeks of ozanimod
induction therapy were then re-randomized at 1:1 to either
ozanimod 1 mg or placebo and outcomes assessed at week 52
(Sandborn W. et al., 2020). Clinical remission (based on 3-
component Mayo score) rates were significantly higher in the
ozanimod group at 37% compared to 18.5% in the placebo group
(p < 0.0001) (Danese et al., 2020a). Anti-TNF exposed patients
who received ozanimod also had a significantly higher rate of
clinical remission compared to placebo (28.9% vs. 10.1; p 
0.0053). All secondary endpoints of the trial were also met in
the ozanimod group including: clinical response, endoscopic
improvement, corticosteroid-free remission, maintenance of
clinical remission, durable clinical remission and mucosal
healing (both endoscopic and histologic) (Danese et al.,
2020a). In this trial, ozanimod was also well tolerated with the
most common reported AEs being abnormal liver tests and
headaches. Elevation of alanine aminotransferase (ALT) was
noted in 4.8% in the ozanimod group compared to 0.4% in
the placebo group (Danese et al., 2020a).
For CD, ozanimod was evaluated in a phase II multicenter,
uncontrolled, prospective observer-blinded endpoint trial,
STEPSTONE (Feagan et al., 2020a). The trial had a 12-
weeks induction period followed by a 100-weeks extension
study. Patients with moderately to severely active CD (n  69)
received a 7-days dose escalation of ozanimod followed by
11 weeks of ozanimod 1 mg oral capsule daily. The primary
endpoint was reduction in the Simple Endoscopic Score for
Crohn’s disease (SES-CD) at 12 weeks from baseline. The
mean change of SES-CD at week 12 was – 2.2 ± 6 and
23.2% of patients achieved endoscopic response (defined as
SES-CD decrease by ≥ 50%) (Feagan et al., 2020a). Clinical
remission (defined as CDAI <150) was noted in 39.1% of
patients. The most common AE was CD flare and there
were no cases of bradycardia or arrhythmias reported
(Feagan et al., 2020a).
Phase III, placebo-controlled induction and maintenance
studies of ozanimod in moderate to severe CD are currently
recruiting (NCT03440372, NCT03440385, NCT03464097,
NCT03467958).
Etrasimod
Etrasimod is an oral S1P receptor modulator with selectivity
for S1PR1, S1PR4 and S1PR5. A phase II (OASIS; proof of
concept), double-blinded trial randomized moderate to severe
UC patients (n  156) to either etrasimod 1 mg, etrasimod
2 mg or placebo in a 1:1:1 fashion for 12 weeks (Sandborn et al.,
2020g). The primary endpoint was improvement in the
modified Mayo Clinic score at 12 weeks from baseline and
secondary endpoints included: the improvement in the total
Mayo Clinic score, improvement in the two component Mayo
Clinic score (rectal bleeding and endoscopy) and endoscopic
improvement (endoscopy sub-score ≤ 1). The primary
endpoint was achieved in the etrasimod 2 mg group
compared to placebo (least square mean difference, 0.99;
90% CI, 0.30–1.68; p  0.009) but not in the etrasimod 1 mg
group. Compared to placebo, the etrasimod 2 mg group had
higher rates of: endoscopic improvement (41.8 vs. 17.8%; p 
0.003), improvement in the total Mayo score (p  0.010) and
improvement in the 2 component Mayo score (p  0.002)
(Sandborn et al., 2020g). Histologic remission (defined as
Geboes score <2) was an exploratory endpoint of the trial
and was significantly higher in the etrasimod 2 mg group
compared to placebo (19.5 vs. 6.1%; p  0.03) (Sandborn
et al., 2020g).
In this trial there was significantly higher rates of
discontinuation of drug due to AEs in the etrasimod groups
(n  7) compared to placebo (n  0) (Sandborn et al., 2020g).
The most common AEs other than disease worsening are upper
respiratory tract infections, nasopharyngitis and anemia. In
etrasimod 2 mg group, transient first-degree heart block
occurred in two patients and type 1 s degree heart block was
noted in one patient. The authors report that all three patients
had evidence of atrioventricular block noted on
electrocardiography prior to receiving the study drug
(Sandborn et al., 2020g).
Phase III induction and maintenance trials of etrasimod for
moderate to severe UC are currently recruiting (NCT03996369,
NCT03945188, NCT03950232, NCT04176588). A phase II/III
study of etrasimod induction and maintenance in CD has
recently opened and is currently recruiting (NCT04173273).
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Amiselimod (MT-1303)
Amiselimod is an oral S1P receptor modulator with higher
selectivity for S1PR1 than other S1P receptors. Phase II study
of amiselimod demonstrated that is well tolerated and potentially
effective for multiple sclerosis (Kappos et al., 2016). A phase II
randomized, placebo-controlled trial of amiselimod in CD
(NCT02378688) was completed and at this time results are
not published. A proof of concept study randomized 78
patients to either amiselimod 0.4 mg (n  40) or placebo (n 
38) (D’Haens et al., 2019). The primary outcomes of clinical
response (decrease in CDAI by 100 points) at week 12 was
achieved in 48.7 vs. 54.1% in the placebo group. No significant
differences were noted in the fecal calprotectin and CRP in the
two groups (D’Haens et al., 2019).
Phosphodiesterase 4 Inhibitors
Phosphodiesterases (PDE1-PDE11) are a group of intracellular
enzymes that catalyze the breakdown of cyclic adenosine
monophosphate (cAMP) and cyclic guanosine monophosphate
(cGMP). PDE4 catalyzes the breakdown of 3, 5′ cAMP in
multiple cell types including T-cells, macrophages and
monocytes. This leads to activation of nuclear transcription
factor kappaB (NF-κB) which eventually promotes
downstream proinflammatory effects. Therefore, inhibition of
PDE4 can lead to suppression of NF-κB and subsequently reduce
TNF-αmRNA expression and production of nitric oxide and also
increase synthesis of anti-inflammatory cytokines such as IL-10
and IL-6 (Ollivier et al., 1996; Gobejishvili et al., 2008; Kwak et al.,
2005; Platzer et al., 1999). Therefore, there has been interest in
developing PDE4 inhibitors as therapeutic agents in IBD.
Apremilast
Apremilast is an oral PDE4 inhibitor that is currently approved
by the US FDA for the treatment of psoriasis and psoriatic
arthritis. A double-blind, phase II trial randomized UC
patients to apremilast 30 mg (n  57), apremilast 40 mg (n 
55) or placebo (n  58) twice daily (Danese et al., 2020b). The
primary endpoint of clinical remission (defined as total Mayo UC
score ≤2; no individual score >1) was achieved in 31.6% in the
30 mg group (p  0.01 compared to placebo), 21.8% in the 40 mg
group compared to 12.1% in the placebo group (p  0.27) (Danese
et al., 2020b). Endoscopic response (defined as a decrease in the
Mayo endoscopic subscore by ≥ 1) was achieved in 41.4% of
patients in the placebo group compared to 73.7% in the 30 mg
group (p < 0.0001) and 47.3% in the 40 mg group (p  0.69). Both
the 30 and 40 mg apremilast groups showed greater reduction in
CPR and fecal calprotectin compared to placebo. Although the
primary endpoint was not reached in this trial, post hoc analysis
demonstrated that a significantly higher proportion of patient in
both apremilast groups had a Mayo endoscopic subscore of ≤1
compared to placebo (Danese et al., 2020b).
In terms of safety, the most common side effect reported in
the apremilast groups were headaches at 25.5% in the 40 mg
group and 21.1% in the 30 mg group compared to 6.9% in the
placebo group. Serious AE rate was 2.4% in the placebo group
and 1.8% in the 40 mg apremilast group (1 patient who
experienced pancreatitis but thought not to be related to
study drug) (Danese et al., 2020b). Currently, a phase III UC
trial of apremilast has not been registered.
Cobitolimod
Cobitolimod is an oligodeoxynucleotide that is DNA-based and
binds to Toll-like receptor 9 (TLR9) on lymphocytes and antigen
presenting cells. It activates TLR 9 which lead to induction of
regulatory T-cells that produce anti-inflammatory IL-10 in
addition to suppressing proinflammatory TH-17 cells.
Cobitolimod is a topical agent and is supposed to have low
systemic absorption.
A double-blind study (COLLECT) randomized 131 patients
with moderate to severe UC to two topically administered doses
(during colonoscopy) of cobitolimod 30 mg (n  87) or placebo
(n  44) (Atreya et al., 2016). The primary endpoint of induction
of clinical remission at week 12 (defined as Clinical Activity Index
(CAI) ≤4) was 44.4% in the cobitolimod group vs. 46.5% in the
placebo group (p  0.91) (Atreya et al., 2016). However, the study
did meet multiple secondary endpoints including symptomatic
remission, clinical remission with mucosal healing and histologic
improvement.
A dose ranging, double-blinded phase IIb study (CONDUCT)
randomized 213 patients with moderate to severe left-sided UC
into five different treatment arms that received drug or placebo
via rectal enemas: cobitolimod 31 mg, 125 mg, or 250 mg at weeks
0 and 3; cobitolimod 125 mg at weeks 0, 1,2 and 3 or placebo
(Atreya et al., 2020). The primary endpoint of clinical remission
at 6 weeks (defined as Mayo subscore of 0 for rectal bleeding, 0 or
1 for stool frequency + ≥ 1-point decrease from baseline,
endoscopy subscore of 0 or 1-excluding friability) was
achieved in the cobitolimod 250 mg group at 21% (n  9) vs.
7% (n  3) in the placebo group (p  0.025) (Atreya et al., 2020).
The rest of the dosing groups did not achieve the primary
endpoint compared to placebo. Cobitolimod was well tolerated
with an adverse event rate across the dosing groups from 25 to
43% compared to 48% in the placebo group (Atreya et al., 2020).
Phase 3 studies are planned for UC (not yet registered at this
time).
CONCLUSION
In conclusion, the armamentarium of IBD therapeutic agents is
ever expanding. This review highlights some of these novel and
emerging therapies. For example, there has been significant
development in the small molecules class of agents such as JAK
inhibitors and S1P receptor modulators. These agents offer the
advantages of ease of administration as they are oral agents and do
not have the downside of immunogenicity and antibody formation
seen with some of the IV/SC biologics. Some of these agents such
might also have the possibility of more rapid onset of action as seen
with tofacitinib. In addition, some of these agents will likely have
the potential of having a more favorable safety profile compared to
anti-TNF agents. This includes for example the development of the
intestinally restricted pan-JAK inhibitor (TD-1473), anti-integrins/
anti-MAdCAM therapies and IL-23 therapies. In the era of
increasing therapeutic agents to treat IBD, the challenge will the
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ability to select the best agent for the individual patient. This calls for
the development of precision/personalizedmedicine approach to the
treatment of IBD.
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